The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. Products that are ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying off. First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) has surged ...

Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter. The shares were worth an estimated $3.60 million. The move marked a full exit from the position, which was previously ...

Fri, January 16, 2026 at 1:06 PM UTC Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...